pyrilamine has been researched along with Body Weight in 4 studies
Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.
mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Histamine was injected subcutaneously to rats at doses of 2--10 mg/kg, twice daily for various periods after an intradermal adjuvant injection into one hind paw." | 5.26 | Inhibition of adjuvant arthritis by histamine. ( Saeki, K; Wake, K; Yamasaki, H, 1976) |
| "Pyrilamine treatment did not reduce survival." | 2.39 | Chronic feeding study of pyrilamine in Fischer 344 rats. ( Allaben, W; Allen, R; Cronin, GM; Dahlgren, R; Greenman, DL, 1995) |
| "Methapyrilene (MPH) was a widely used antihistamine until it was found to produce hepatocellular carcinoma and cholangiocarcinoma in Fischer 344 rats." | 1.29 | The hepatocarcinogen methapyrilene but not the analog pyrilamine induces sustained hepatocellular replication and protein alterations in F344 rats in a 13-week feed study. ( Anderson, NL; Cunningham, ML; Pippin, LL; Wenk, ML, 1995) |
| "Histamine was injected subcutaneously to rats at doses of 2--10 mg/kg, twice daily for various periods after an intradermal adjuvant injection into one hind paw." | 1.26 | Inhibition of adjuvant arthritis by histamine. ( Saeki, K; Wake, K; Yamasaki, H, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greenman, DL | 1 |
| Cronin, GM | 1 |
| Dahlgren, R | 1 |
| Allen, R | 1 |
| Allaben, W | 1 |
| Cunningham, ML | 1 |
| Pippin, LL | 1 |
| Anderson, NL | 1 |
| Wenk, ML | 1 |
| Saeki, K | 1 |
| Wake, K | 1 |
| Yamasaki, H | 1 |
| Wong, CL | 1 |
| Roberts, MB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study[NCT00661674] | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The OOWS is a 13-item instrument documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score possible = 13, minimum score possible = 0. T=15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~OOWS scores at T=180 is the primary outcome measure of the study compared with baseline OOWS scores at T=-30 (30 minutes prior to study medication administration). Reported time frames are in relation to time past since administration of study medications.~Mean post-Naloxone OOWS scores (+/- SEM) were determined for pretreatment groups" (NCT00661674)
Timeframe: Change from baseline in OOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (OOWS Scale) (Mean) |
|---|---|
| Placebo | 3.5 |
| Palonosetron | 1.0 |
| Palonosetron + Hydroxyzine | 0 |
"The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. 15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~The highest score possible (64) would indicate that the individual was experiencing every symptom of opioid withdrawal to the fullest extent possible while the lowest score (0) would indicate that the individual was not experiencing any symptoms of opioid withdrawal.~Mean post-naloxone SOWS scores (+/- SEM) were computed for pretreatment groups: Placebo, palonosetron, and palonosetron with hydroxyzine" (NCT00661674)
Timeframe: Change from baseline in SOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (SOWS Scale) (Mean) |
|---|---|
| Placebo | 6.0 |
| Palonosetron | 4.0 |
| Palonosetron + Hydroxyzine | 3.5 |
1 review available for pyrilamine and Body Weight
| Article | Year |
|---|---|
Chronic feeding study of pyrilamine in Fischer 344 rats.
Topics: Adrenal Medulla; Animals; Body Weight; Carcinogenicity Tests; Carcinogens; Eating; Endocrine Gland N | 1995 |
3 other studies available for pyrilamine and Body Weight
| Article | Year |
|---|---|
The hepatocarcinogen methapyrilene but not the analog pyrilamine induces sustained hepatocellular replication and protein alterations in F344 rats in a 13-week feed study.
Topics: Administration, Oral; Animals; Body Weight; Carcinogens; Cell Division; Dose-Response Relationship, | 1995 |
Inhibition of adjuvant arthritis by histamine.
Topics: Adjuvants, Immunologic; Animals; Arthritis; Body Weight; Burimamide; Histamine; Histamine H1 Antagon | 1976 |
The effects of L-histidine and of specific histamine receptor agonists, on the expression of morphine tolerance and physical dependence in mice.
Topics: Animals; Body Weight; Drug Interactions; Drug Tolerance; Female; Histidine; Humans; Male; Metiamide; | 1976 |